Cargando…
The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy
Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375741/ https://www.ncbi.nlm.nih.gov/pubmed/22708037 http://dx.doi.org/10.4084/MJHID.2012.022 |
_version_ | 1782235779028746240 |
---|---|
author | Brusamolino, Ercole Gotti, Manuel Fiaccadori, Valeria |
author_facet | Brusamolino, Ercole Gotti, Manuel Fiaccadori, Valeria |
author_sort | Brusamolino, Ercole |
collection | PubMed |
description | Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, this risk has substantially been reduced. In this review, different experiences are discussed to determine whether and how modifications of treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. These data are drawn from large cohorts of patients treated over time with different therapies with an adequate follow-up. |
format | Online Article Text |
id | pubmed-3375741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-33757412012-06-15 The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy Brusamolino, Ercole Gotti, Manuel Fiaccadori, Valeria Mediterr J Hematol Infect Dis Review Articles Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, this risk has substantially been reduced. In this review, different experiences are discussed to determine whether and how modifications of treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. These data are drawn from large cohorts of patients treated over time with different therapies with an adequate follow-up. Università Cattolica del Sacro Cuore 2012-04-06 /pmc/articles/PMC3375741/ /pubmed/22708037 http://dx.doi.org/10.4084/MJHID.2012.022 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Brusamolino, Ercole Gotti, Manuel Fiaccadori, Valeria The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title | The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title_full | The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title_fullStr | The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title_full_unstemmed | The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title_short | The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy |
title_sort | risk of therapy-related myelodysplasia/acute myeloid leukemia in hodgkin lymphoma has substantially decreased in the abvd era abolishing mechlorethamine and procarbazine and limiting volumes and doses of radiotherapy |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375741/ https://www.ncbi.nlm.nih.gov/pubmed/22708037 http://dx.doi.org/10.4084/MJHID.2012.022 |
work_keys_str_mv | AT brusamolinoercole theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT gottimanuel theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT fiaccadorivaleria theriskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT brusamolinoercole riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT gottimanuel riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy AT fiaccadorivaleria riskoftherapyrelatedmyelodysplasiaacutemyeloidleukemiainhodgkinlymphomahassubstantiallydecreasedintheabvderaabolishingmechlorethamineandprocarbazineandlimitingvolumesanddosesofradiotherapy |